科研动态PubMed 摘要

抗gp210抗体在原发性胆汁性胆管炎中的预后价值:一项系统评价与荟萃分析。

PubMed 学科轮询 · 2026-01-01

完整摘要 · 中文译文

背景:原发性胆汁性胆管炎(PBC)是一种慢性胆汁淤积性肝病,以门管区炎症和免疫介导的非化脓性破坏性胆管炎为特征。近期研究表明,抗gp210抗体与PBC的预后相关。在此,我们对anti-gp210抗体与PBC患者预后之间的关系进行了汇总分析,以期早期识别高危患者并提供个体化干预。 方法:检索PubMed、EMBASE、Cochrane对照试验中心注册库和Web of Science数据库,检索截止至2025年1月。当不存在统计学显著异质性时,采用固定效应模型和95%置信区间(CI)进行荟萃分析;否则采用随机效应统计模型。 结果:本系统评价和荟萃分析共纳入12条记录。我们的荟萃分析结果显示,与anti-gp210阴性患者相比,anti-gp210阳性PBC患者的肝衰竭发生率(相对危险度(RR),6.11;95% CI,3.16-11.81)和死亡率(RR,1.92;95% CI,1.55-2.37)更高,熊去氧胆酸(UDCA)应答率更低(RR,0.81;95% CI,0.73-0.89)。此外,anti-gp210抗体的存在与PBC患者不良预后独立相关(风险比(HR),4.53;95% CI,2.83-7.26)。此外,anti-gp210阳性PBC患者的血清γ-谷氨酰转肽酶(GGT)(均数差(MD),53.03;95% CI,3.70-102.36)、免疫球蛋白M(IgM)(MD,1.29;95% 95%置信区间(CI,0.80-1.78)以及免疫球蛋白G(IgG)(平均差(MD),1.06;95%CI,0.07-2.06)水平,以及较低的白蛋白(MD,-1.74;95%CI,-2.80至-0.69)水平。 结论:总之,抗gp210阳性的原发性胆汁性胆管炎(PBC)患者预后较抗gp210阴性者更差。将抗gp210检测纳入临床实践可增强风险分层并指导个体化管理,最终改善这一脆弱人群的结局。

完整摘要 · 英文原文

BACKGROUND: Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease characterized by portal inflammation and immune-mediated nonsuppurative destructive cholangitis. Recent studies have shown that anti-gp210 antibodies are associated with the prognosis of PBC. Here, we conducted a pooled analysis of the relationship between anti-gp210 antibodies and the prognosis of PBC patients to identify high-risk patients early and provide individualized interventions. METHODS: PubMed, EMBASE, Cochrane Central Register of Controlled Trials, and Web of Science databases were searched until January 2025. A meta-analysis was undertaken using a fixed-effects model and 95% confidence interval (CI) when no statistically significant heterogeneity existed; otherwise, a random-effects statistical model was used. RESULTS: A total of 12 records were included in this systematic review and meta-analysis. The results of our meta-analysis showed that anti-gp210 positive PBC patients had a higher incidence of liver failure (relative risk (RR), 6.11; 95% CI, 3.16-11.81) and mortality (RR, 1.92; 95% CI, 1.55-2.37) and a lower ursodeoxycholic acid (UDCA) response rate (RR, 0.81; 95% CI, 0.73-0.89) compared with anti-gp210 negative patients. Moreover, the presence of anti-gp210 antibodies was independently associated with a poor prognosis in patients with PBC (hazard ratios (HR), 4.53; 95% CI, 2.83-7.26). In addition, anti-gp210 positive PBC patients had higher serum gamma-glutamyl transpeptidase (GGT) (mean difference (MD), 53.03; 95% CI, 3.70-102.36), immunoglobulin M (IgM) (MD, 1.29; 95% CI, 0.80-1.78), and immunoglobulin G (IgG) (MD, 1.06; 95% CI, 0.07-2.06) levels and lower albumin (MD, -1.74; 95% CI, -2.80 to - 0.69) levels. CONCLUSION: In conclusion, PBC patients with positive anti-gp210 have a worse prognosis than those with negative anti-gp210. Incorporating anti-gp210 testing into clinical practice could enhance risk stratification and guide personalized management, ultimately improving outcomes for this vulnerable population.

English
Prognostic value of anti-gp210 antibodies in primary biliary cholangitis: A Systematic review and meta-analysis.
内容仅供参考,不构成诊疗建议,不能替代执业医师的诊断。

← 返回元界